A copayment increase for prescription drugs: The long-term and short-term effects on use and expenditures

Inquiry

Volumn 42, Issue 3, 2005, Pages 293-310

  Gibson, Teresa B ^a,c   McLaughlin, Catherine G ^b   Smith, Dean G ^b  

^a Research Division of Medstat   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Medstat   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; ATTENUATION; CHRONIC DISEASE; DISEASE MANAGEMENT; ELASTICITY; EMPLOYEE; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MEDICAL FEE; OUTPATIENT; PRESCRIPTION;

EID: 28544439412     PISSN: 00469580     EISSN: None     Source Type: Journal    
DOI: 10.5034/inquiryjrnl_42.3.293     Document Type: Article

References (42)

1. Ai, C., and E.G. Norton. 2003. Interaction Terms in Logit and Probit Models. Economics Letters 80(1): 123-129.
2. Berndt, E.R. 2001. The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment? Health Affairs 20(2): 100-114.
3. Bertrand, M., E. Duflo, and S. Mullainathan. 2004. How Much Should We Trust Difference-in-Differences Estimates? Quarterly Journal of Economics 119(1): 249-275.
4. Blough, D.K., C.W. Madden, and M.C. Hornbrook. 1999. Modeling Risk Using Generalized Linear Models. Journal of Health Economics 18(2): 153-171.
5. Briesacher, B., S. Kamal-Bahl, M. Hochberg, et al. 2004. Three-Tiered Copayment Drug Coverage and Use of Nonsteroidal Anti-inflammatory Drugs. Archives of Internal Medicine 164(15): 1679-1684.
6. Buntin, M.B., and A.M. Zaslavsky. 2004. Too Much Ado About Two-Part Models and Transformation? Comparing Methods of Modeling Medicare Expenditures. Journal of Health Economics 23(3): 525-542.
7. Cameron, A.C., and P.K. Trivedi. 1998. Regression Analysis of Count Data. Cambridge, U.K.: Cambridge University Press.
8. Chernew, M.E., D.G. Smith, D.M. Kirking, and A.M. Fendrick. 2001. Decomposing Pharmaceutical Cost Growth in Different Types of Health Plans. American Journal of Managed Care 7(7): 667-673.
9. Diehr, P., D. Yanez, A. Ash, M. C. Hornbrook, and D.Y. Lin. 1999. Methods for Analyzing Health Care Utilization and Costs. Annual Review of Public Health 20:125-144.
10. Dietz, E. 2004. Trends in Employer-Provided Prescription-Drug Coverage. Monthly Labor Review 127(8): 37-45.
11. Dubois, R.W., A.J. Chawla, C.A. Neslusan, M.A. Smith, and S. Wade. 2000. Explaining Drug Spending Trends: Does Perception Match Reality? Health Affairs 19(2): 231-239.
12. Fairman, K.A., B.R. Motheral, and R.R. Henderson. 2003. Retrospective, Long-Term Follow-Up Study of the Effect of a Three-Tier Prescription Drug Copayment System on Pharmaceutical and Other Medical Utilization and Costs. Clinical Therapeutics 25(12): 3147-3161.
13. Goldman, D.P., G.F. Joyce, and J.J. Escarce, et al. 2004. Pharmacy Benefits and the Use of Drugs by the Chronically III. Journal of the American Medical Association 291(19): 2344-2350.
14. Gonnella, J.S., M.C. Hornbrook, and D.Z. Lewis. 1984. Staging of Disease: A Case-Mix Measurement. Journal of the American Medical Association 251(5): 637-644.
15. Grossman, M. 2000. The Human Capital Model. In Handbook of Health Economics, Vol. 1A, A.J. Culyer and J.P. Newhouse, eds. Amsterdam and New York: Elsevier.
16. Harris, B.L., A. Stergachis, and L.D. Ried. 1990. The Effect of Drug Co-Payments on Utilization and Cost of Pharmaceuticals in a Health Maintenance Organization. Medical Care 28(10): 907-917.
17. Heckman, J.J., H. Ichimura, and P. Todd. 1997. Matching as an Econometric Evaluation Estimator: Evidence from Evaluating a Job Training Programme. Review of Economic Studies 64(4): 605-654.
18. Hillman, A.L., M.V. Pauly, J.J. Escarce, K. Ripley, M. Gaynor, J. Clouse, and R. Ross. 1999. Financial Incentives and Drug Spending in Managed Care. Health Affairs 18(2): 189-200.
19. Huskamp, H.A., P.A. Deverka, and A.M. Epstein, et al. 2003. The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending. New England Journal of Medicine 349(23): 2224-2232.
20. Jacobson, L.S., R.J. LaLonde, and D.G. Sullivan. 1993. Earnings Losses of Displaced Workers. American Economic Review 83(4): 685-709.
21. Johnson, R.E., M.J. Goodman, M.C. Hornbrook, and M.B. Eldredge. 1997. The Impact of Increasing Patient Prescription Drug Cost Sharing on Therapeutic Classes of Drugs Received and on the Health Status of Elderly HMO Members. Health Services Research 32(1): 103-122.
22. Joyce, G.F., J.J. Escarce, M.D. Solomon, and D.P. Goldman. 2002. Employer Drug Benefit Plans and Spending on Prescription Drugs. Journal of the American Medical Association 288(14): 1733-1739.
23. Kaiser Family Foundation. 2004. Employer Health Benefits 2004 Annual Survey. Available at: www.kff.org.
24. Kamal-Bahl, S., and B. Briesacher. 2004. How Do Incentive-Based Formularies Influence Drug Selection and Spending for Hypertension? Health Affairs 23(1): 227-236.
25. Konetzka, R.T. D. Yi, E.G. Norton, and K.E. Kilpatrick. 2004. Effects of Medicare Payment Changes on Nursing Home Staffing and Deficiencies. Health Services Research 39(3): 463-488.
26. Liang, K.-Y., and S.L. Zeger. 1986. Longitudinal Data Analysis Using Generalized Linear Models. Biometrika 73(1): 13-22.
27. Lipsitz, S.R., G.M. Fitzmaurice, E.J. Orav, and N.M. Laird. 1994. Performance of Generalized Estimating Equations in Practical Situations. Biometrics 50(1): 270-278.
28. Manning, W.G., J.P. Newhouse, N. Duan, E.B. Keeler, A. Leibowitz, and M.S. Marquis. 1987. Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment. American Economic Review 77(3): 251-277.
29. Meyer, B.D. 1995. Natural and Quasi-Experiments in Economics. Journal of Business and Economic Statistics 13(2): 151-161.
30. Motheral, B.R., and R. Henderson. 1999. The Effect of a Copay Increase on Pharmaceutical Utilization, Expenditures and Treatment Continuation. American Journal of Managed Care 5(11): 1383-1394.
31. Motheral, B.R., and K.A. Fairman. 2001. Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization. Medical Care 39(12): 1293-1304.
32. Nelson, A.A., C.E. Reeder, and W.M. Dickson. 1984. The Effect of a Medicaid Drug Copayment Program on the Utilization and Cost of Prescription Services. Medical Care 22(8): 724-736.
33. Pharmaceutical Research and Manufacturers of America (PhRMA). 2002. Pharmaceutical Industry Profile 2002. Washington, D.C.: Pharmaceutical Research and Manufacturers of America.
34. Remler, O.K., and A.J. Atherly. 2003. Health Status and Heterogeneity of Cost-Sharing Responsiveness: How Do Sick People Respond to Cost-Sharing? Health Economics 12(4): 269-280.
35. Rosenbaum, P.R., and D.B. Rubin. 1983. The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika 70(1): 41-55.
36. Smith, D.G. 1993. The Effects of Copayments and Generic Substitution on the Use and Costs of Prescription Drugs. Inquiry 30(2): 189-198.
37. -. 1997/98. The Effects of Preferred Provider Organizations on Health Care Use and Costs. Inquiry 34(4): 278-287.
38. Smith, C., C. Cowan, A. Sensenig, et al. 2005. Health Spending Growth Slows in 2003. Health Affairs 24(1): 185-194.
39. Tai-Seale, M., D. Freund, and A. LoSasso. 2001. Racial Disparities in Service Use among Medicare Beneficiaries after Mandatory Enrollment in Managed Care: A Difference-in-Differences Approach. Inquiry 38(1): 49-59.
40. Tamblyn, R., R. Laprise, J.A. Hanley, M. Abrahamowicz, S. Scott, N. Mayo, J. Hurley, R. Grad, E. Latimer, R. Perreault, P. McLeod, A. Huang, P. Larochelle, and L. Mallet. 2001. Adverse Events Associated with Prescription Drug Cost-Sharing Among Poor and Elderly Persons. Journal of the American Medical Association 285(4): 421-429.
41. Thomas, C.P., S.S. Wallack, S. Lee, and G. Ritter. 2002. Impact of Health Plan Design and Management on Retirees' Prescription Drug Use and Spending, 2001. Health Affairs Web Exclusive. W408-W419.
42. White, H. 1980. A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity. Econometrica 48(3): 817-830.